With the conduct of multiple clinical trials for gastric cancer, programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) monoclonal antibodies have been approved for first-line treatment of advanced gastric cancer, and the application of immunotherapy in the perioperative period of gastric cancer is also being explored. Here, PDCD1 is linked to gastric cancer.